TriangleNCT02903914 · OUTCOME
Tmax of INCB001158 Following Multiple Escalating Doses for Part 1A
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- hours
- Interval / dispersion
- Full Range
- Time frame
- Cycle 1 Day 15: predose; 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose
What was measured
tmax was defined as the time of the maximum observed concentration of INCB001158.
Analysis population: PK Population
Groups in this outcome
Part 1A: INCB001158 50 mg
INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.
Part 1A: INCB001158 75 mg
INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.
Part 1A: INCB001158 100 mg
INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.
Part 1A: INCB001158 150 mg
INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.
| Group | Source count |
|---|---|
| Part 1A: INCB001158 50 mg | 6 |
| Part 1A: INCB001158 75 mg | 7 |
| Part 1A: INCB001158 100 mg | 7 |
| Part 1A: INCB001158 150 mg | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1A: INCB001158 50 mg | 2.0 | Not reported | 1.9 | 4.0 | Not reported |
| Part 1A: INCB001158 75 mg | 4.1 | Not reported | 2.0 | 6.1 | Not reported |
| Part 1A: INCB001158 100 mg | 4.0 | Not reported | 2.1 | 5.9 | Not reported |
| Part 1A: INCB001158 150 mg | 2.0 | Not reported | 1.9 | 4.2 | Not reported |
Source statistical analyses
- group Ids
- OG000
- OG001
- OG002
- OG003
- non Inferiority Type
- OTHER
- p Value
- 0.0518
- statistical Method
- Kruskal-Wallis
Complete source fields
- analyses
- group Ids
- OG000
- OG001
- OG002
- OG003
- non Inferiority Type
- OTHER
- p Value
- 0.0518
- statistical Method
- Kruskal-Wallis
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.9
- upper Limit
- 4.0
- value
- 2.0
- group Id
- OG001
- lower Limit
- 2.0
- upper Limit
- 6.1
- value
- 4.1
- group Id
- OG002
- lower Limit
- 2.1
- upper Limit
- 5.9
- value
- 4.0
- group Id
- OG003
- lower Limit
- 1.9
- upper Limit
- 4.2
- value
- 2.0
- denoms
- counts
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 7
- group Id
- OG003
- value
- 6
- units
- Participants
- description
- tmax was defined as the time of the maximum observed concentration of INCB001158.
- dispersion Type
- Full Range
- groups
- description
- INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.
- id
- OG000
- title
- Part 1A: INCB001158 50 mg
- description
- INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.
- id
- OG001
- title
- Part 1A: INCB001158 75 mg
- description
- INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.
- id
- OG002
- title
- Part 1A: INCB001158 100 mg
- description
- INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.
- id
- OG003
- title
- Part 1A: INCB001158 150 mg
- param Type
- MEDIAN
- population Description
- PK Population
- reporting Status
- POSTED
- time Frame
- Cycle 1 Day 15: predose; 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose
- title
- Tmax of INCB001158 Following Multiple Escalating Doses for Part 1A
- type
- SECONDARY
- unit Of Measure
- hours
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice